1. From the Ontario Cancer Institute, Division of Cellular and Molecular Biology, Toronto, Ontario, Canada; the Lymphocyte Biology Section, Department of Rheumatology and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; the Division of Hematology and Medical Oncology, Oregon Health Sciences University, Portland; and the Division of Pediatric Oncology and Division of Cellular and Molecular Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.